
EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma
August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract
Updated on: October 12,2023
6

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma
August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract
Updated on:October 12,2023
6
